Associate Professor of Medicine, Mayo Medical School
Oncology
Dr. Donald W. Northfelt, MD
Donald W. Northfelt works in the field of Oncology. He studied medicine at University of Minnesota Medical School. University of Minnesota Medical School is ranked 40/10 in Research/PrimaryCare. He has 13 awards "America's Top Doctors", "Top Doctors:Arizona State", "America's Top Doctors for Cancer", "AMERICA'S TOP DOCTOR", "Commissioned as Colonel, Staff of the Governor of Kentucky", "Above and Beyond Award", "Gloria Greene Inspiration Award", "Volunteer of the Year", "Special Recognition Award", "Livermore Award in Hematology", "Zagaria Fellowship in Oncology", "Alpha Omega Alpha" and "Williams Memorial Scholarship". Dr. Donald W. Northfelt is a published doctor. He has 36 papers published. The most current publication "Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients." He is registered with Medicare and accepts Medicare payments.
Publications
- Temporal Trends of Cardiac Chambers Function with Trastuzumab in Human Epidermal Growth Factor Receptor II-Positive Breast Cancer Patients.
- Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
- Quality of life and disease understanding: impact of attending a patient-centered Cancer symposium.
- Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors.
- A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321.
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma.
- Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
- Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast Cancer participating in E5103.
- Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.
- Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung Cancer.
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast Cancer.
- Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.
- Advanced basal cell Carcinoma of the skin: targeting the hedgehog pathway.
- Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer.
- A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer: NCCTG Study N0338.
- The Impact of Obesity on Breast Cancer: A Retrospective Review.
- Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast Cancer patients enrolled in North Central Cancer Treatment Group (NCCT...
- Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular Cancer.
- Triple-negative breast Cancers: unique clinical presentations and outcomes.
- Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast Cancer: time for a second look?
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast Cancer.
- A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patie...
- Live, attenuated varicella zoster vaccination of an immunocompromised patient.
- Trastuzumab-induced cardiotoxicity: heart failure at the crossroads.
- Impact of pretreatment factors on adverse events: a pooled Analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials.
- 74-year-old woman with dyspnea on exertion and Anemia.
- The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung Cancer.
- Use of liposomal anthracyclines in Kaposi's sarcoma.
- Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast Cancer.
- A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.
- Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of Chronic malignant or no...
- Intersection of cardiology and oncology clinical practices.
Schools
University Of Minnesota Medical School
University Of California Los Angeles
Procedures Preformed
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna
- American Enterprise Group
- American Republic
- Assurant Health
- Blue Card PPO
- Cofinity PPO
- Commercial Insurance Company
- Delta Health System
- Golden Rule
- GEHA
- HealthPartners
- HealthSmart
- Humana
- Medicaid
- Medicare MCR
- Meritain Health
- MVP Health Care
- PacificSource
- Simplifi
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:Arizona State
- America's Top Doctors for Cancer
- AMERICA'S TOP DOCTOR
- Commissioned as Colonel, Staff of the Governor of Kentucky
- Above and Beyond Award
- Gloria Greene Inspiration Award
- Volunteer of the Year
- Special Recognition Award
- Livermore Award in Hematology
- Zagaria Fellowship in Oncology
- Alpha Omega Alpha
- Williams Memorial Scholarship
Education
-
UCSF
-
UCLA Medical Center
-
University of Minnesota Medical School
Hospital
-
Mayo Clinic - Phoenix/Scottsdale, Arizona
Drug Facts
| NPI NUMBER |
|
1316922008 |
| NPPES Provider LastName |
|
NORTHFELT |
| NPPES Provider FirstName |
|
DONALD |
| NPPES Provider ZIPCode |
|
852595404 |
| NPPES Provider State |
|
AZ |
| Specialty Description |
|
Medical Oncology |
| Total Claim Count |
|
297.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1316922008 |
| Last Name Of The Provider |
NORTHFELT |
| First Name Of The Provider |
DONALD |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.